1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Increasing Burden of Alzheimer's Disease Globally
4.2.2. Rising Prevalence of Risk Factors
4.2.3. Increase in Research Funding
4.2.4. Introduction of Innovative Technologies
4.2.5. Increasing Number of Approvals
4.2.6. Increasing Number of Clinical Trials and Pipeline Products
4.3. Restraints
4.3.1. Possible Side Effects of Drugs
4.3.2. Use of Substitute Treatment
4.4. Opportunities
4.4.1. Growing Research Activities in Developing Countries
4.4.2 Increase in Awareness Programs
4.4.3. Initiatives by Public and Private Organizations
4.4.4. Use of Combination Drug Therapy
4.4.5. Use of Biomarkers and Imaging Techniques for Diagnosis and Management
4.5. Challenges
4.5.1. High Cost of Research and Development for Alzheimer’s Drugs
4.5.2. High Failure Rate in Clinical Trials for Alzheimer’s Drugs
4.5.3. Lengthy and Complex Regulatory Approval Process for Alzheimer’s Drugs
4.6. Factor Analysis
4.7. Trends
4.8. Regulatory Analysis
4.9. Pricing Analysis
4.10. Pipeline Analysis
4.11. Porter’s Five Force Analysis
5. Alzheimer’s Drugs Market Assessment—by Drug Type
5.1. Overview
5.2. Cholinesterase Inhibitors
5.2.1. Donepezil
5.2.2. Galantamine
5.2.3. Rivastigmine
5.3. NMDA receptor antagonists
5.4. Glutamate regulators
5.5. Combination Drugs
6. Alzheimer’s Drugs Market Assessment—by Application
6.1. Overview
6.2. Disease Progression
6.3. Symptoms Management
6.3.1. Dementia
6.3.2. Insomnia
6.3.3. Other Symptoms
7. Alzheimer’s Drugs Market Assessment—by Geography
7.1. Overview
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Switzerland
7.3.7. Belgium
7.3.8. Rest of Europe (RoE)
7.4. Asia-Pacific
7.4.1. Japan
7.4.2. China
7.4.3. India
7.4.4. South Korea
7.4.5. Rest of Asia-Pacific (RoAPAC)
7.5. Latin America
7.5.1. Brazil
7.5.2. Mexico
7.5.3. Argentina
7.5.4. Rest of Latin America (RoLATAM)
7.6. Middle East & Africa
7.6.1. UAE
7.6.2. Saudi Arabia
7.6.3. South Africa
7.6.4. Rest of Middle East & Africa
8. Competition Analysis
8.1. Overview
8.2. Key Growth Strategies
8.3. Competitive Benchmarking
8.4. Competitive Dashboard
8.4.1. Industry Leaders
8.4.2. Market Differentiators
8.4.3. Vanguards
8.4.4. Emerging Companies
8.5. Market Share Analysis/Market Ranking, by Key Players (2023)
9. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)
9.1. Biogen
9.2. Novartis AG
9.3. F. Hoffmann-La Roche AG
9.4. AbbVie Inc.
9.5. Teva Pharmaceutical Industries Ltd.
9.6. Eisai Co., Ltd.
9.7. SUPERNUS PHARMACEUTICALS, INC.
9.8. H. Lundbeck A/S
9.9. AC Immune SA
9.10. Zydus Lifesciences Limited
9.11. Johnson & Johnson
9.12. Daiichi Sankyo Company
(Note: SWOT analyses of the top 5 companies will be provided.)
10. Appendix
10.1. Available Customization
10.2. Related Reports
List of Tables
Table 1 Global Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 2 Global Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 3 Global Cholinesterase Inhibitors Market, by Country/Region, 2022–2031 (USD Million)
Table 4 Global Donepezil Market, by Country/Region, 2022–2031 (USD Million)
Table 5 Global Galantamine Market, by Country/Region, 2022–2031 (USD Million)
Table 6 Global Rivastigmine Market, by Country/Region, 2022–2031 (USD Million)
Table 7 Global NMDA receptor antagonists Market, by Country/Region, 2022–2031 (USD Million)
Table 8 Global Glutamate Regulators Market, by Country/Region, 2022–2031 (USD Million)
Table 9 Global Combination Drugs Market, by Country/Region, 2022–2031 (USD Million)
Table 10 Global Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 11 Global Alzheimer’s Drugs Market for Disease Progression, by Country/Region, 2022–2031 (USD Million)
Table 12 Global Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 13 Global Alzheimer’s Drugs Market for Symptoms Management, by Country/Region, 2022–2031 (USD Million)
Table 14 Global Alzheimer’s Drugs Market for Dementia, by Country/Region, 2022–2031 (USD Million)
Table 15 Global Alzheimer’s Drugs Market for Insomnia, by Country/Region, 2022–2031 (USD Million)
Table 16 Global Alzheimer’s Drugs Market for Other Symptoms, by Country/Region, 2022–2031 (USD Million)
Table 17 Global Alzheimer’s Drugs Market, by Country/Region, 2022–2031 (USD Million)
Table 18 North America: Alzheimer’s Drugs Market, by Country, 2022–2031 (USD Million)
Table 19 North America: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 20 North America: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 21 North America: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 22 North America: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 23 U.S.: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 24 U.S.: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 25 U.S.: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 26 U.S.: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 27 Canada: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 28 Canada: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 29 Canada: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 30 Canada: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 31 Europe: Alzheimer’s Drugs Market, by Country/Region, 2022–2031 (USD Million)
Table 32 Europe: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 33 Europe: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 34 Europe: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 35 Europe: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 36 Germany: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 37 Germany: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 38 Germany: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 39 Germany: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 40 France: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 41 France: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 42 France: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 43 France: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 44 U.K.: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 45 U.K.: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 46 U.K.: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 47 U.K.: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 48 Italy: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 49 Italy: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 50 Italy: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 51 Italy: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 52 Spain: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 53 Spain: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 54 Spain: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 55 Spain: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 56 Switzerland: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 57 Switzerland: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 58 Switzerland: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 59 Switzerland: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 60 Belgium: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 61 Belgium: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 62 Belgium: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 63 Belgium: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 64 Rest of Europe: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 65 Rest of Europe: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 66 Rest of Europe: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 67 Rest of Europe: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 68 Asia-Pacific: Alzheimer’s Drugs Market, by Country/Region, 2022–2031 (USD Million)
Table 69 Asia-Pacific: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 70 Asia-Pacific: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 71 Asia-Pacific: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 72 Asia-Pacific: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 73 China: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 74 China: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 75 China: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 76 China: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 77 Japan: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 78 Japan: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 79 Japan: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 80 Japan: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 81 India: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 82 India: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 83 India: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 84 India: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 85 South Korea: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 86 South Korea: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 87 South Korea: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 88 South Korea: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 89 Rest of Asia-Pacific: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 90 Rest of Asia-Pacific: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 91 Rest of Asia-Pacific: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 92 Rest of Asia-Pacific: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 93 Latin America: Alzheimer’s Drugs Market, by Country/Region, 2022–2031 (USD Million)
Table 94 Latin America: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 95 Latin America: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 96 Latin America: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 97 Latin America: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 98 Brazil: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 99 Brazil: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 100 Brazil: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 101 Brazil: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 102 Mexico: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 103 Mexico: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 104 Mexico: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 105 Mexico: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 106 Argentina: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 107 Argentina: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 108 Argentina: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 109 Argentina: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 110 Rest of Latin America: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 111 Rest of Latin America: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 112 Rest of Latin America: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 113 Rest of Latin America: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 114 Middle East & Africa: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 115 Middle East & Africa: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 116 Middle East & Africa: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 117 Middle East & Africa: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 118 UAE: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 119 UAE: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 120 UAE: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 121 UAE: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 122 Saudi Arabia: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 123 Saudi Arabia: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 124 Saudi Arabia: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 125 Saudi Arabia: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 126 South Africa: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 127 South Africa: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 128 South Africa: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 129 South Africa: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 130 Rest of Middle East & Africa: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 131 Rest of Middle East & Africa: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 132 Rest of Middle East & Africa: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 133 Rest of Middle East & Africa: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 134 Recent Developments, by Company, 2020–2024
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Global Alzheimer’s Drugs Market, by Drug Type, 2024 VS. 2031 (USD Million)
Figure 8 Global Alzheimer’s Drugs Market, by Application, 2024 VS. 2031 (USD Million)
Figure 9 Global Alzheimer’s Drugs Market, by Geography
Figure 10 Global Alzheimer’s Drugs Market, by Drug Type, 2024 VS. 2031 (USD Million)
Figure 11 Global Alzheimer’s Drugs Market, by Application, 2024 VS. 2031 (USD Million)
Figure 12 Global Alzheimer’s Drugs Market, by Geography, 2024 VS. 2031 (USD Million)
Figure 13 North America: Alzheimer’s Drugs Market Snapshot
Figure 14 Europe: Alzheimer’s Drugs Market Snapshot
Figure 15 Asia-Pacific: Alzheimer’s Drugs Market Snapshot
Figure 16 Latin America: Alzheimer’s Drugs Market Snapshot
Figure 17 Middle East & Africa: Alzheimer’s Drugs Market Snapshot
Figure 18 Key Growth Strategies Adopted by Leading Players, 2020–2024
Figure 19 Global Alzheimer’s Drugs Market: Competitive Benchmarking, by Drug Type
Figure 20 Global Alzheimer’s Drugs Market: Competitive Benchmarking, by Geography
Figure 21 Global Alzheimer’s Drugs Market: Competitive Dashboard
Figure 22 Global Alzheimer’s Drugs Market: Market Share Analysis/Market Ranking, By Key Players (2023)
Figure 23 Biogen: Financial Snapshot (2023)
Figure 24 Novartis AG: Financial Snapshot (2023)
Figure 25 F. Hoffmann-La Roche AG: Financial Snapshot (2023)
Figure 26 AbbVie Inc.: Financial Snapshot (2023)
Figure 27 Teva Pharmaceutical Industries Ltd.: Financial Snapshot (2023)
Figure 28 Eisai Co., Ltd.: Financial Snapshot (2023)
Figure 29 SUPERNUS PHARMACEUTICALS, INC.: Financial Snapshot (2023)
Figure 30 H. Lundbeck A/S: Financial Snapshot (2023)
Figure 31 AC Immune SA: Financial Snapshot (2023)
Figure 32 Zydus Lifesciences Limited: Financial Snapshot (2023)
Figure 33 Johnson & Johnson: Financial Snapshot (2023)
Figure 34 Daiichi Sankyo Company: Financial Snapshot (2023)